12,910 Shares of DexCom, Inc. $DXCM Bought by Radnor Capital Management LLC

Radnor Capital Management LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,910 shares of the medical device company’s stock, valued at approximately $1,114,000.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Mather Group LLC. lifted its stake in DexCom by 27.7% during the third quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock worth $49,000 after purchasing an additional 122 shares during the period. Fifth Third Wealth Advisors LLC boosted its holdings in DexCom by 2.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after purchasing an additional 150 shares in the last quarter. Elevation Wealth Partners LLC grew its stake in shares of DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB grew its stake in shares of DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 153 shares during the period. Finally, Simplicity Wealth LLC grew its stake in shares of DexCom by 5.4% in the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock valued at $273,000 after purchasing an additional 162 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 3,638 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. The trade was a 2.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,257 shares of company stock worth $2,049,173 over the last ninety days. 0.28% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. BTIG Research raised their target price on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a research note on Sunday, September 6th. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the company a “buy” rating in a research report on Monday, August 3rd. UBS Group set a $96.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Wells Fargo & Company increased their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, DexCom presently has a consensus rating of “Buy” and an average target price of $92.43.

DexCom Price Performance

NASDAQ:DXCM opened at $77.94 on Friday. The firm has a market cap of $29.41 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average price is $86.79 and its two-hundred day moving average price is $76.54.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 earnings per share. On average, equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.